amg 199

AMG 199 is a novel half-life extended (HLE) bispecific T cell engager (BiTE) antibody construct developed for the treatment of solid tumors, particularly those expressing MUC17 such as gastric and gastroesophageal junction cancers. It is designed to bind both CD3 on T cells and MUC17 on tumor cells, thereby redirecting T cell cytotoxicity specifically toward tumor cells. The molecule incorporates variable domains from two monoclonal antibodies—one targeting CD3 and the other targeting MUC17—linked via a flexible linker and fused to an Fc domain to extend serum half-life through neonatal Fc receptor recycling. Upon administration, AMG 199 mediates the formation of a cytolytic synapse between host T cells and MUC17-expressing tumor cells, leading to targeted tumor cell lysis via release of perforin and granzymes, as well as induction of proinflammatory cytokines[1][2][4][5][7].

Other names

anti-MUC17/CD3 BiTE antibody